Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Galantamine Hydrobromide
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Essential Pharma
Deal Size : Undisclosed
Deal Type : Acquisition
Essential Pharma Acquires Reminyl® (galantamine hydrobromide) Capsules
Details : Essential Pharma has acquired rights to Reminyl (galantamine), a cholinesterase inhibitor, for the EEA, Thailand, South Korea, and other markets, excluding the UK and Japan.
Product Name : Reminyl
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 17, 2024
Lead Product(s) : Galantamine Hydrobromide
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Essential Pharma
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Galantamine Hydrobromide,Metformin
Therapeutic Area : Musculoskeletal
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Rejuvenate Biomed Announces Positive Results from Phase 1b Clinical Trial with RJx-01 in Sarcopenia
Details :
Product Name : RJx-01
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 10, 2023
Lead Product(s) : Galantamine Hydrobromide,Metformin
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Galantamine Hydrobromide
Therapeutic Area : Musculoskeletal
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Rejuvenate Biomed Started a Groundbreaking Clinical Trial and Expands for Future Growth
Details :
Product Name : RJx-01
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 29, 2022
Lead Product(s) : Galantamine Hydrobromide
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable